Aureka Secures $100 Million in Latest Series B Funding Round

Aureka secured $100 million in its latest Series B, adding another data point to the Robotics funding market.

Aureka Raises $100 million in Funding

Aureka lands $100M series B to scale AI drug discovery. Aureka Biotechnologies is an AI-native TechBio company building next-generation biological foundation models and closed-loop AI-native infrastructure to transform the therapeutic discovery process.

Investors Behind the Funding

The round was backed by Menlo Ventures’ Anthology Fund. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Aureka operates in Robotics. Aureka's financing adds to recent private-market activity.

Strategic Use of Funds

scale AI drug discovery

Looking Ahead

Aureka lands $100M series B to scale AI drug discovery

Source reference: original announcement/article.